Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stake Raised by Northern Trust Corp

Northern Trust Corp boosted its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 792,750 shares of the company's stock after purchasing an additional 55,144 shares during the period. Northern Trust Corp owned approximately 0.93% of Syndax Pharmaceuticals worth $10,480,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Virtus ETF Advisers LLC grew its stake in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after acquiring an additional 827 shares in the last quarter. E Fund Management Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 14.4% during the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock valued at $167,000 after acquiring an additional 1,583 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock valued at $239,000 after acquiring an additional 1,732 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $26,000. Finally, Y Intercept Hong Kong Ltd lifted its position in shares of Syndax Pharmaceuticals by 2.5% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 83,297 shares of the company's stock worth $1,101,000 after purchasing an additional 1,995 shares during the last quarter.

Syndax Pharmaceuticals Trading Down 8.9%

NASDAQ SNDX traded down $0.96 during trading hours on Friday, reaching $9.85. The company's stock had a trading volume of 3,902,175 shares, compared to its average volume of 1,770,764. The business has a 50-day simple moving average of $11.83 and a 200 day simple moving average of $13.80. Syndax Pharmaceuticals, Inc. has a 52 week low of $8.58 and a 52 week high of $25.07. The stock has a market cap of $847.56 million, a PE ratio of -2.71 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million during the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the business earned ($0.85) EPS. The business's revenue was up 1900.0% on a year-over-year basis. As a group, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SNDX. Citigroup reduced their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. JPMorgan Chase & Co. increased their price target on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. Scotiabank increased their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research report on Tuesday, May 6th. Finally, Wall Street Zen raised shares of Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).